Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | N1068Kfs*5 |
Impact List | frameshift |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA N1068Kfs*5 indicates a shift in the reading frame starting at the final amino acid of the Pik3ca protein, 1068, and terminating 5 residues downstream, resulting in extension of the Pik3ca protein length by 3 amino acids (UniProt.org). N1068Kfs*5 results in increased cell proliferation, migration, and Akt phosphorylation compared to wild-type Pik3ca (PMID: 34779417), and increased transformation ability in several different cell lines in culture (PMID: 29533785, PMID: 34779417). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA N1068Kfs*5 PIK3CA mutant PIK3CA exon21 PIK3CA N1068Kfs*5 |
Transcript | NM_006218.4 |
gDNA | chr3:g.179234360dupA |
cDNA | c.3203dupA |
Protein | p.N1068Kfs*5 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006218 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179234360dupA | c.3203dupA | p.N1068Kfs*5 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|